Executives
-
Altshuler DavidEVP, Chief Scientific Officer -
Kewalramani ReshmaCEO & President
-
Biller JonathanEVP and Chief Legal Officer
-
Leiden Jeffrey MExecutive Chairman
-
Bozic CarmenEVP and CMO
-
Atkinson Edward Morrow IiiEVP, Chief Technical Ops. Off.
-
Sachdev AmitEVP Chief Patient & Ext Af Off
-
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
-
Ambrose KristenSVP & Chief Accounting Officer
?
Ambrose Kristen
SVP & Chief Accounting Officer
Vertex Pharmaceuticals Incorporated
US, Boston [HQ]
CIK
1856587
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
7,740
Price per Share :
$419.92
Equivalence :
$3,250,180.80
Transaction History
-
F7,740 Shares After TransactionValue : $3,236,094.00$94,072.50Transaction Date : 04/01/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.
-
S7,500 Shares After TransactionValue : $3,142,500.00Sold $100,560.00Transaction Date : 04/02/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.
-
F8,848 Shares After TransactionValue : $3,820,477.92$357,522.12Transaction Date : 02/23/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.
-
S7,965 Shares After TransactionValue : $3,390,700.50Sold $375,893.10Transaction Date : 02/26/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.
-
A9,788 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/06/24
-
Footnotes
-
-
Footnotes:#1 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.#2 Restricted stock unit award that vests in installments beginning on 02/17/2025.